Eledon Pharmaceuticals（ELDN）株式概要エレドン・ファーマシューティカルズ社は臨床段階のバイオテクノロジー企業である。 詳細ELDN ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析収益が 100 万ドル未満 ( $0 )今後3年間の収益は年平均7%減少すると予測されている。 現在は利益が出ておらず、今後3年間で利益が出る見込みはない 過去1年間で株主の希薄化が進んだ すべてのリスクチェックを見るELDN Community Fair Values Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$3.84該当なし内在価値ディスカウントEst. Revenue$PastFuture-129m192016201920222025202620282031Revenue US$19.0Earnings US$3.4AdvancedSet Fair ValueView all narrativesEledon Pharmaceuticals, Inc. 競合他社Nuvectis PharmaSymbol: NasdaqCM:NVCTMarket cap: US$273.2mInhibikase TherapeuticsSymbol: NasdaqCM:IKTMarket cap: US$267.6mREGENXBIOSymbol: NasdaqGS:RGNXMarket cap: US$292.6mZentalis PharmaceuticalsSymbol: NasdaqGM:ZNTLMarket cap: US$252.0m価格と性能株価の高値、安値、推移の概要Eledon Pharmaceuticals過去の株価現在の株価US$3.8452週高値US$4.6052週安値US$1.35ベータ0.951ヶ月の変化-7.25%3ヶ月変化72.97%1年変化21.90%3年間の変化80.28%5年間の変化-56.85%IPOからの変化-96.66%最新ニュースお知らせ • Apr 22Eledon Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2026Eledon Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2026. Location: 19800 macarthur boulevard, suite 250, california., irvine United States分析記事 • Mar 24Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...お知らせ • Mar 16Eledon Pharmaceuticals Announces Updated Data From Investigator-Initiated Islet Transplant Trial Of Tegoprubart In Patients With Type 1 Diabetes At UChicago MedicineEledon Pharmaceuticals, Inc. announced updated results from an investigator-initiated trial conducted at the University of Chicago Medicine Transplant Institute and presented by Piotr Witkowski, M.D., Ph.D., Director of the Pancreas and Islet Transplant Program at UChicago Medicine, at the Advanced Technologies and Treatments for Diabetes (ATTD) conference, held March 11-14, 2026 in Barcelona, Spain. The investigator-initiated pilot study enrolled 12 adults with long-standing type 1 diabetes undergoing allogeneic islet transplantation at UChicago Medicine. Patients had a median duration of diabetes of approximately 33 years and mean hemoglobin A1C (“HbA1C”) of approximately 8.0% prior to transplantation. Participants received tegoprubart, Eledon’s anti-CD40L monoclonal antibody, as part of a calcineurin inhibitor-free immunosuppression regimen. The data demonstrated rapid improvement in glycemic control following islet transplantation, with stable islet graft function observed across the cohort. All 10 patients who were more than four weeks post-transplant achieved both insulin independence and a most recent HbA1c below 6.0%, with a mean most recent HbA1c across the 10 patients of approximately 5.35%. Tegoprubart-based immunosuppression was generally well tolerated with reported post-transplant immunosuppression-related adverse events successfully treated by lowering the mycophenolic acid dose, if necessary. There were no rejection episodes, and no patients developed de novo donor-specific HLA antibodies. Additionally, no evidence of nephrotoxicity, hypertension or neurotoxicity, which are commonly associated with tacrolimus-based immunosuppression regimens, was observed. These findings further support the potential of CD40L blockade to enable effective islet graft protection while avoiding the toxicities of calcineurin inhibitors. This UChicago Medicine-initiated clinical trial is funded by Breakthrough T1D, with initial support from The Cure Alliance. Breakthrough T1D has also committed to fund a second study evaluating tegoprubart as part of a calcineurin inhibitor-free immunosuppression drug regimen to prevent islet transplant rejection in individuals with T1D and chronic kidney disease. Pancreatic islet transplantation is a minimally invasive procedure developed to provide blood glucose control for subjects with type 1 diabetes and minimize or eliminate dependence on insulin. During the procedure, pancreatic islets containing insulin-producing beta cells are isolated from the pancreas of a deceased organ donor and infused through a small catheter into the patient’s liver. The islet cells lodge in small blood vessels in the liver and release insulin. After the procedure, subjects remain on immunosuppression therapy to prevent transplant rejection.お知らせ • Mar 10Eledon Pharmaceuticals, Inc. Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver TransplantationEledon Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to tegoprubart for the prevention of allograft rejection in liver transplantation. Tegoprubart has previously received orphan drug designation from the FDA for the prevention of allograft rejection in pancreatic islet cell transplantation and for the treatment of amyotrophic lateral sclerosis (ALS). Orphan Drug Designation is intended to support the development of therapies for rare diseases, defined as conditions affecting fewer than 200,000 people in the United States or fewer than 5 in 10,000 individuals in the European Union. These designations provide sponsors with a range of incentives intended to encourage the development of medicines for diseases with high unmet medical needs.お知らせ • Jan 23Eledon Pharmaceuticals Presents Long-Term Phase 1B Data for Tegoprubart in Kidney Transplant Patients At the American Society of Transplant Surgeons Winter SymposiumEledon Pharmaceuticals, Inc. announced that it will present 24-month follow-up data from eight patients enrolled in the Phase 1b trial long-term extension evaluating tegoprubart in kidney transplantation at the American Society of Transplant Surgeons Winter Symposium, taking place January 23-25, 2026, in Scottsdale, Arizona. There were no episodes of biopsy-proven acute rejection, graft loss, death, new-onset diabetes mellitus, or de Novo donor-specific antibody formation during the study period. Mean estimated glomerular filtration rate (eGFR) increased over the measurement period, from 67.0 mL/min/1.73 m2 at 12 months to 74.2 mL/min/1. 73 m2 at 24 months.New Risk • Jan 09New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 33% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (33% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$115m net loss in 3 years).最新情報をもっと見るRecent updatesお知らせ • Apr 22Eledon Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2026Eledon Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2026. Location: 19800 macarthur boulevard, suite 250, california., irvine United States分析記事 • Mar 24Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...お知らせ • Mar 16Eledon Pharmaceuticals Announces Updated Data From Investigator-Initiated Islet Transplant Trial Of Tegoprubart In Patients With Type 1 Diabetes At UChicago MedicineEledon Pharmaceuticals, Inc. announced updated results from an investigator-initiated trial conducted at the University of Chicago Medicine Transplant Institute and presented by Piotr Witkowski, M.D., Ph.D., Director of the Pancreas and Islet Transplant Program at UChicago Medicine, at the Advanced Technologies and Treatments for Diabetes (ATTD) conference, held March 11-14, 2026 in Barcelona, Spain. The investigator-initiated pilot study enrolled 12 adults with long-standing type 1 diabetes undergoing allogeneic islet transplantation at UChicago Medicine. Patients had a median duration of diabetes of approximately 33 years and mean hemoglobin A1C (“HbA1C”) of approximately 8.0% prior to transplantation. Participants received tegoprubart, Eledon’s anti-CD40L monoclonal antibody, as part of a calcineurin inhibitor-free immunosuppression regimen. The data demonstrated rapid improvement in glycemic control following islet transplantation, with stable islet graft function observed across the cohort. All 10 patients who were more than four weeks post-transplant achieved both insulin independence and a most recent HbA1c below 6.0%, with a mean most recent HbA1c across the 10 patients of approximately 5.35%. Tegoprubart-based immunosuppression was generally well tolerated with reported post-transplant immunosuppression-related adverse events successfully treated by lowering the mycophenolic acid dose, if necessary. There were no rejection episodes, and no patients developed de novo donor-specific HLA antibodies. Additionally, no evidence of nephrotoxicity, hypertension or neurotoxicity, which are commonly associated with tacrolimus-based immunosuppression regimens, was observed. These findings further support the potential of CD40L blockade to enable effective islet graft protection while avoiding the toxicities of calcineurin inhibitors. This UChicago Medicine-initiated clinical trial is funded by Breakthrough T1D, with initial support from The Cure Alliance. Breakthrough T1D has also committed to fund a second study evaluating tegoprubart as part of a calcineurin inhibitor-free immunosuppression drug regimen to prevent islet transplant rejection in individuals with T1D and chronic kidney disease. Pancreatic islet transplantation is a minimally invasive procedure developed to provide blood glucose control for subjects with type 1 diabetes and minimize or eliminate dependence on insulin. During the procedure, pancreatic islets containing insulin-producing beta cells are isolated from the pancreas of a deceased organ donor and infused through a small catheter into the patient’s liver. The islet cells lodge in small blood vessels in the liver and release insulin. After the procedure, subjects remain on immunosuppression therapy to prevent transplant rejection.お知らせ • Mar 10Eledon Pharmaceuticals, Inc. Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver TransplantationEledon Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to tegoprubart for the prevention of allograft rejection in liver transplantation. Tegoprubart has previously received orphan drug designation from the FDA for the prevention of allograft rejection in pancreatic islet cell transplantation and for the treatment of amyotrophic lateral sclerosis (ALS). Orphan Drug Designation is intended to support the development of therapies for rare diseases, defined as conditions affecting fewer than 200,000 people in the United States or fewer than 5 in 10,000 individuals in the European Union. These designations provide sponsors with a range of incentives intended to encourage the development of medicines for diseases with high unmet medical needs.お知らせ • Jan 23Eledon Pharmaceuticals Presents Long-Term Phase 1B Data for Tegoprubart in Kidney Transplant Patients At the American Society of Transplant Surgeons Winter SymposiumEledon Pharmaceuticals, Inc. announced that it will present 24-month follow-up data from eight patients enrolled in the Phase 1b trial long-term extension evaluating tegoprubart in kidney transplantation at the American Society of Transplant Surgeons Winter Symposium, taking place January 23-25, 2026, in Scottsdale, Arizona. There were no episodes of biopsy-proven acute rejection, graft loss, death, new-onset diabetes mellitus, or de Novo donor-specific antibody formation during the study period. Mean estimated glomerular filtration rate (eGFR) increased over the measurement period, from 67.0 mL/min/1.73 m2 at 12 months to 74.2 mL/min/1. 73 m2 at 24 months.New Risk • Jan 09New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 33% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (33% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$115m net loss in 3 years).お知らせ • Nov 20Eledon Pharmaceuticals, Inc. Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at U Chicago MedicineEledon Pharmaceuticals, Inc. announced preliminary results from an investigator-initiated trial conducted at the University of Chicago Medicine's Transplant Institute and presented at the Rachmiel Levine-Arthur Riggs Diabetes Research Symposium, held November 14-17, 2025 at City of Hope in Los Angeles, California. The ongoing trial, which has been extended to include a total of 12 subjects, is evaluating tegoprubart, Eledon's investigational anti-CD40 Ligand (anti-CD40L) antibody, as the core of a tacrolimus-free immunosuppression drug regimen for the prevention of islet transplant rejection in individuals with type 1 diabetes (T1D). The results, presented by Piotr Witkowski, M.D., Ph.D., Director of the Pancreas and Islet Transplant Program at UChicago Medicine, provide updated preliminary data on the first six subjects in the trial, demonstrating the ability of tegoprubart to prevent the rejection of transplanted islet cells in the absence of calcineurin inhibition resulting in sustained insulin-free management of hemoglobin A1C (HbA1c) in patients with T1D. This clinical trial is funded by Breakthrough T1D (formerly JDRF), with initial support from The Cure Alliance. Breakthrough T1D has also committed to fund a second study evaluating tegoprubart as part of a calcineurin inhibitor-free immunosuppression Drug regimen to prevent islet transplant rejection in individuals With T1D and chronic kidney disease. Post-procedure, subjects remain on immunosuppression therapy to prevent transplant rejection.New Risk • Nov 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings are forecast to decline by an average of 15% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$129m net loss in 3 years). Shareholders have been diluted in the past year (26% increase in shares outstanding).New Risk • Nov 16New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$83m Forecast net loss in 3 years: US$129m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings are forecast to decline by an average of 15% per year for the foreseeable future. Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$129m net loss in 3 years).お知らせ • Nov 13Eledon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $49.986448 million.Eledon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $49.986448 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 15,152,485 Price\Range: $1.65 Discount Per Security: $0.099 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 15,151,515 Price\Range: $1.649 Discount Per Security: $0.099Price Target Changed • Nov 12Price target decreased by 14% to US$8.17Down from US$9.50, the current price target is an average from 6 analysts. New target price is 332% above last closing price of US$1.89. Stock is down 56% over the past year. The company is forecast to post a net loss per share of US$0.83 next year compared to a net loss per share of US$0.75 last year.お知らせ • Nov 12Eledon Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.Eledon Pharmaceuticals, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Security Name: Pre-Funded Warrants Security Type: Equity WarrantPrice Target Changed • Nov 10Price target decreased by 12% to US$9.00Down from US$10.20, the current price target is an average from 6 analysts. New target price is 337% above last closing price of US$2.06. Stock is down 58% over the past year. The company is forecast to post a net loss per share of US$0.82 next year compared to a net loss per share of US$0.75 last year.お知らせ • Nov 07Eledon Pharmaceuticals, Inc. Presents Phase 2 Bestow Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation At the American Society of Nephrology's Kidney Week 2025 Annual MeetingEledon Pharmaceuticals, Inc. announced results from its Phase 2 BESTOW trial evaluating tegoprubart for the prevention of organ rejection in patients receiving a de novo kidney transplant. Results from the Phase 2 BESTOW clinical trial were presented as a late breaking oral presentation titled "Efficacy and Safety of Tegoprubart for the Prevention of Rejection in Kidney Transplantation: Results from the Phase 2 BESTow Trial," at the American Society of Nephrology's Kidney Week 2025 Annual Meeting in Houston, TX. The study's primary efficacy endpoint was the change in eGFR at 12 months post-transplant. Secondary endpoints included biopsy-proven acute rejection (BPAR), patient and graft survival, composite efficacy failure, iBox score, donor-specific antibodies (DSAs), delayed graft function (DGF), and new-onset diabetes after transplantation (NODAT). Safety findings underscore tegoprubart's potential to maintain effective immunosuppression while minimizing the metabolic, neurologic, and cardiovascular toxicities characteristic of tacrolimus-based therapy. eGFR on tegoprubart treatment was 69 mL/min/1.73 m2 (n=51) at 12 months vs. 66 mL/min/1. 73 m2 for tacrolimus (n=56). Although the primary endpoint did not reach statistical significance, tegoprubart maintained strong renal function, delivering what the Company believes is the highest mean eGFR level reported to date in kidney transplant clinical trials evaluating rejection prevention. Subgroup analyses demonstrated higher eGFRs in nearly all tegoprubart subgroups compared with tacrolimus, particularly among living-related donor recipients (72 mL/min/1.74 m2 vs. 62 mL/min/1.72 m2) and high Kidney Donor Profile Index (KDPI > 35) transplants (62 mL/min/1.83 m2 vs. 53 mL/min/1.1.73 m2). The efficacy failure composite endpoint, comprising death, graft loss and biopsy proven acute rejection, is the approval endpoint currently recognized by the U.S. Food and Drug Administration.Valuation Update With 7 Day Price Move • Nov 02Investor sentiment improves as stock rises 24%After last week's 24% share price gain to US$4.32, the stock trades at a trailing P/E ratio of 17.7x. Average trailing P/E is 18x in the Biotechs industry in the US. Total returns to shareholders of 79% over the past three years.Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improves as stock rises 26%After last week's 26% share price gain to US$3.44, the stock trades at a trailing P/E ratio of 14.1x. Average trailing P/E is 16x in the Biotechs industry in the US. Total returns to shareholders of 45% over the past three years.お知らせ • Oct 17Eledon Pharmaceuticals to Present Results from Phase 2 Bestow Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual MeetingEledon Pharmaceuticals, Inc. announced an oral presentation will be featured at the American Society of Nephrology's upcoming Kidney Week 2025 Annual Meeting taking place in Houston, TX, from November 5-8, 2025. The oral presentation will highlightline results from the Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation.New Risk • Aug 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 21% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (52% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$124m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change).お知らせ • Aug 07Eledon Pharmaceuticals, Inc. Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney TransplantationEledon Pharmaceuticals, Inc. announced updated data from the Company's ongoing open-label Phase 1b trial evaluating tegoprubart for the prevention of organ rejection in kidney transplant patients. Results from the oral presentation, titled "Tegoprubart, an Anti-CD40L Antibody, for the Prevention of Rejection in Kidney Transplantation: An Ongoing Phase 1b Study," were presented at the World Transplant Congress (WTC) taking place in San Francisco, CA. Data from historical studies using the standard of care, calcineurin inhibitor-based immunosuppression therapy, typically report aggregate mean estimated glomerular filtration rates (eGFRs) of approximately 53 mL/min/1.73 m2 during the first year after kidney transplant. In addition, preliminary abbreviated iBox data was presented suggesting that tegoprubart may improve 5-year graft survival. Abbreviated iBox, a composite biomarker panel developed by the Paris Transplant Group, incorporates kidney function (eGFR, proteinuria) and immunologic response (donor-specific antibodies) parameters into a single prognostic score. Of the patients who experienced a rejection episode and completed a year in the study, three who remained on tegoprubart had a mean eGFR of approximately 73 mL/min/1. 73 m2 at 12 months, indicating full recovery of kidney function, while the two patients who switched to standard of care tacrolimus had a mean eGFR the mean eGFR of approximately 34 mL/min/1.73 m2 at 12 months.お知らせ • Jul 09Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance A Potential Functional Cure for Type 1 DiabetesSernova Biotherapeutics announced a Collaborative Research Agreement with Eledon Pharmaceuticals, Inc. to evaluate Eledon's immunosuppressive agent tegoprubart (AT-1501) in Sernova's ongoing Phase 1/2 clinical trial of its Cell Pouch Bio-hybrid Organ in patients with type 1 diabetes (T1D). Under the terms of the agreement, Eledon will supply tegoprubart, an investigational anti-CD40L antibody being evaluated for its potential to prevent transplant rejection in islet cell, kidney and xeno transplantation, will be used in place of tacrolimus in the upcoming Cohort C of Sernova's Phase 1/2 clinical trial. Tacrolimus is currently a standard immunosuppressive drug used in organ transplantation to prevent rejection. However, its potential toxicity, particularly toward insulin-producing beta cells, and its side effect profile limit its suitability as an optimal immunosuppressive agent for islet cell therapy in T1D. In an investigator-initiated study led by Dr. Piotr Witkowski, a leading expert in islet transplantation at the University of Chicago, T1D patients received islet transplants along with tegoprubart to prevent rejection. Islet engraftment, measured by graft function standardized to the number of islets infused, was three to five times higher than in comparable subjects outside this study who received tacrolimus-based immunosuppression, suggesting treatment with tegoprubart better protects transplanted islets resulting in improved graft survival and function. Treatment was generally well tolerated in all subjects with no unexpected adverse events or severe hypoglycemic episodes. This collaboration highlights the shared commitment of both companies to address the unmet needs of individuals living with T1D. By combining their expertise and leveraging complementary technologies, Sernova and Eledon aim to deliver a therapeutic solution that offers a durable and effective alternative to daily insulin injections and current immunosuppressive protocols.Price Target Changed • May 21Price target decreased by 12% to US$9.00Down from US$10.20, the current price target is an average from 4 analysts. New target price is 186% above last closing price of US$3.15. Stock is up 5.4% over the past year. The company is forecast to post a net loss per share of US$0.87 next year compared to a net loss per share of US$0.75 last year.分析記事 • May 07Companies Like Eledon Pharmaceuticals (NASDAQ:ELDN) Are In A Position To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...お知らせ • Apr 15Eledon Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2025Eledon Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2025. Location: at 19800 macarthur boulevard, suite 250, california, irvine United StatesSeeking Alpha • Jan 28Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management BusinessSummary Eledon Pharmaceuticals' Tegoprubart, a second-gen anti-CD40L antibody, shows promise in preventing organ rejection without thromboembolic risks, addressing unmet needs in kidney and islet cell transplantation. Early trials indicate Tegoprubart's safety and efficacy, with no major side effects and better kidney function compared to current standards like tacrolimus. Eledon has a market cap of $264mn, a cash balance of $78mn, and a cash runway of 7-8 quarters, but remains a high-risk investment. While it's too early for large investments, a small pilot position could be warranted based on promising early data and unmet medical needs. Read the full article on Seeking AlphaPrice Target Changed • Nov 14Price target decreased by 20% to US$12.50Down from US$15.60, the current price target is an average from 5 analysts. New target price is 193% above last closing price of US$4.27. Stock is up 242% over the past year. The company is forecast to post a net loss per share of US$1.16 next year compared to a net loss per share of US$4.73 last year.お知らせ • Oct 30+ 2 more updatesEledon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $84.9951 million.Eledon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $84.9951 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 18,356,173 Price\Range: $3.65 Discount Per Security: $0.219 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 4,931,507 Price\Range: $3.649 Discount Per Security: $0.219Seeking Alpha • Oct 29Eledon: Changing Scope Of Immunosuppressive Drug Space With TegoprubartSummary Positive phase 1b biomarker and eGFR data achieved from phase 1b study using tegoprubart for prevention of organ rejection in kidney transplant patients. Top-line data from the phase 2 BESTOW study, using tegoprubart for prevention of organ rejection in kidney transplant patients, expected in Q4 of 2025. The organ transplant immunosuppressant drugs market is expected to reach $6.4 billion by 2030. Positive data obtained from investigator-sponsored phase 1/2 trial, using tegoprubart for islet cell transplantation in patients with Type 1 Diabetes. Read the full article on Seeking Alphaお知らせ • Sep 21Eledon Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.Eledon Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offeringお知らせ • Aug 15Eledon Pharmaceuticals, Inc. announced delayed 10-Q filingOn 08/14/2024, Eledon Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jul 29Eledon Pharmaceuticals, Inc. Provides Enrollment Update for Phase 2 Bestow Trial Assessing Tegoprubart for the Prevention of Organ RejectionEledon Pharmaceuticals, Inc. announced that it has enrolled the 80th participant in its ongoing Phase 2 BESTOW trial assessing tegoprubart for the prevention of rejection in kidney transplantation. This progress underscores the urgency and need for innovative solutions in preventing kidney transplant rejection. The study's primary objective is to assess graft function at 12 months post-transplant, as measured by estimated glomerular filtration rate (eGFR), in participants treated with tegoprubart compared to tacrolimus. Better graft function as assessed by eGFR has been associated with improved long-term patient and graft survival. Eledon is currently conducting a Phase 2 trial (BESTOW; NCT05983770), a Phase 1b trial (NCT05027906), and a long-term safety and efficacy extension study (NCT06126380) to evaluate tegop Rubart for the prevention of organ rejection in patients receiving a kidney transplant.お知らせ • Jun 05Eledon Pharmaceuticals, Inc. Presents Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney TransplantationEledon Pharmaceuticals, Inc. presented updated data from the Company’s ongoing open-label Phase 1b trial and open-label extension study evaluating tegoprubart for the prevention of organ rejection in kidney transplant patients. Results from the poster, titled “Biomarkers of Inflammation and eGFR in an Ongoing Phase 1B Study of an Anti-CD40L Antibody Tegoprubart, for the Prevention of Rejection in Kidney Transplant,” were presented at the American Transplant Congress (ATC) taking place in Philadelphia, PA from June 1-5, 2024. As of the April 2024 cutoff date, updated data from the 13 participants in the ongoing Phase 1b trial support tegoprubart’s potential to protect organ function in patients undergoing kidney transplantation. Data from historical studies using standard of care, calcineurin inhibitor-based immunosuppression therapy typically report aggregate mean estimated glomerular filtration rates (eGFRs) of approximately 50 mL/min/1.73m2 during the first year after kidney transplant. In the ongoing Phase 1b trial, mean eGFR was above 60 mL/min/1.73m² at each reported time points after day 30, with an overall mean eGFR of 70.5 mL/min/1.73m² for all the reported time points after day 30 post-transplant. Two participants completed 12 months on therapy post-transplant, and both demonstrated mean eGFRs above 90 mL/min/1.73m² at one-year post-transplant. Results demonstrated that tegoprubart is generally safe and well tolerated in patients undergoing de novo kidney transplantation. Three subjects have discontinued the study due to hair loss and fatigue, viral infection, and rejection, respectively. There have been no cases of hyperglycemia, new onset diabetes, or tremor, all of which are side effects often associated with standard of care immunosuppression therapy. There have been no cases of graft loss or death. Eledon is currently conducting a Phase 1b trial (NCT05027906), a Phase 2 trial (BESTOW; NCT05983770), and a long-term safety and efficacy extension study (NCT06126380) to evaluate tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant.お知らせ • Jun 02Eledon Pharmaceuticals, Inc., Annual General Meeting, Jul 10, 2024Eledon Pharmaceuticals, Inc., Annual General Meeting, Jul 10, 2024. Location: 19800 macarthur boulevard, suite 250, california, irvine United StatesNew Risk • May 27New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 71% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 18% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (71% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$75m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change).Price Target Changed • May 10Price target decreased by 10% to US$14.00Down from US$15.60, the current price target is an average from 5 analysts. New target price is 506% above last closing price of US$2.31. Stock is down 4.1% over the past year. The company is forecast to post a net loss per share of US$1.24 next year compared to a net loss per share of US$1.64 last year.お知らせ • May 08+ 1 more updateEledon Pharmaceuticals, Inc. announced that it expects to receive $49.99901 million in fundingEledon Pharmaceuticals, Inc. announced that it has entered into a Securities Purchase Agreement with certain institutional and accredited investors to issue 13,110,484 shares of the common stock, $0.001 par value per share at a price of $2.37 per share for the gross proceeds of $31,071,847.08 and 7,989,516 pre-funded warrants at a price of $2.369 per warrant for the gross proceeds of $18,927,163.404; for total gross proceeds of $49,999,010.484 on May 6, 2024. The warrants are exercisable to purchase 7,989,516 shares of Common Stock at an exercise price of $0.001 per share. The Pre-Funded Warrants were issued in lieu of shares of Common Stock and are exercisable immediately and until exercised in full. The closing of the Private Placement is expected to occur the week of May 6, 2024. The Shares, the Pre-Funded Warrants, and the shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants, have not been registered under the Securities Act of 1933, as amended, and were offered pursuant to the exemption from registration provided in Section 4(a)(2) under the Securities Act of 1933, as amended, and Rule 506(b) promulgated thereunder.New Risk • Apr 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 25% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (80% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$90m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$49.4m market cap).お知らせ • Mar 26Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ RejectionEledon Pharmaceuticals, Inc. announced the enrollment of the 12th participant on March 23, 2024, in the Company’s ongoing Phase 2 BESTOW trial assessing tegoprubart head-to-head with tacrolimus for the prevention of rejection in kidney transplantation.分析記事 • Mar 22We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth CarefullyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Dec 05Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...お知らせ • Nov 03Eledon Pharmaceuticals, Inc. Reports Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney TransplantationEledon Pharmaceuticals, Inc. reported results from the Company's ongoing Phase 1b open-label trial evaluating tegoprubart for the prevention of rejection in patients undergoing de novo kidney transplantation. Results were presented at the American Society of Nephrology Kidney Week 2023 Annual Meeting taking place in Philadelphia, PA from November 2-5, 2023. Aggregate mean estimated glomerular filtration rate (eGFR) -- a measure of kidney function -- was above 70 mL/min/1.73m(2) at all reported time points after day 90. Historical studies have reported average eGFRs generally in the low 50 mL/min/1. 73m(2) range during the first year after kidney transplant using standard of care. One participant has completed the study with an eGFR of 91 at one year (day 374) and is now enrolled in a Phase 2 open-label extension (OLE) study, which will evaluate the long-term safety, pharmacokinetics, and efficacy of tegoprubart in participants who have completed one year of treatment in either the ongoing Phase 1b or Phase 2 BESTOW study. The Phase 1b open-label study has enrolled 11 participants who underwent kidney transplantation in Canada, Australia, and the United Kingdom. The webcast will be archived on the website following the completion of the call.お知らせ • Oct 24Eledon Pharmaceuticals, Inc. Appoints of Eliezer Katz as Chief Medical OfficerEledon Pharmaceuticals, Inc. announced the appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer with responsibility for leading the company’s clinical development programs. Dr. Katz is an experienced transplant surgeon with significant clinical development experience. Most recently, he was Chief Medical Officer at eGenesis where he helped lead the clinical development of eGenesis’ xenotransplantation programs. Prior to eGenesis, Dr. Katz was Vice President of Clinical Development first at Viela Bio and then at Horizon Therapeutics following its acquisition of Vielo Bio. At Horizon and Viela Bio, Dr. Katz led the clinical development of inebilizumab in multiple autoimmune indications and oversaw the regulatory submission and approval of UPLIZNA(inebilizumab) to treat neuromyelitis optica spectrum disorder in adults. Prior to Viela Bio, Dr. Katz served as Senior Director of Clinical Development at MedImmune Inc. where he oversaw the clinical development of three different biologics. Prior to MedImmune, Dr. Katz served as Senior Director of Transplantation with the Medicine Development Group at Pfizer. At Pfizer, he oversaw multiple research programs with rapamycin, an anti-rejection drug, and was instrumental in the regulatory submission and FDA approval of rapamycin as a treatment for lymphangioleiomyomatosis (LAM), a rare and fatal lung disease. Before joining industry, Dr. Katz spent two decades as a transplant surgeon. He was director of the abdominal transplantation division at Integris Baptist Medical Center in Oklahoma City, and an associate professor of surgery and the director of the liver transplantation division at the University of Massachusetts Medical Center, Worcester, MA.Dr. Katz spearheaded liver transplantation advances at these institutions and was actively involved with policy making in organ donation and allocation. Dr. Katz earned his M.D. at Hadassah Hebrew University Medical School in Jerusalem.Board Change • Oct 13Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. Director Jim Robinson was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 05Eledon Pharmaceuticals Appoints Allan Douglas Kirk to Board of DirectorsEledon Pharmaceuticals, Inc. announced the appointment of Allan Douglas Kirk, M.D., Ph.D., to its Board of Directors. Dr. Kirk is internationally recognized for his work in organ transplantation, with a specialized focus on kidney transplants and transplant immunology. He is currently Chairman of the Department of Surgery and Surgeon-in-Chief at Duke University School of Medicine. He is also the David C. Sabiston, Jr. Professor of Surgery, a Professor of Integrative Immunobiology, and a Professor of Pediatrics at Duke. Dr. Kirk served as the inaugural Chief of the Transplantation Branch for the National Institute of Diabetes and Digestive and Kidney Diseases and has been a principal investigator for multiple clinical trials, including the first-in-human experience with novel immunosuppressive agents. Dr. Kirk has helped pioneer the use of co-stimulation pathway blockade to prevent organ rejection in transplant patients. He has a special interest in immune management of transplant recipients, including therapies that influence T cell co-stimulation pathways and adjuvant therapies that facilitate co-stimulation blockade to prevent the rejection of transplanted organs without undue suppression of protective immunity. His research is directed toward understanding transplant rejection and translating this understanding into improved therapies for transplant recipients. He has co-authored hundreds of peer-reviewed journal publications. Dr. Kirk is a member of the Duke Transplant Center and is a core faculty member of the Duke Innovation & Entrepreneurship program. He also previously served as Editor-in-Chief for the American Journal of Transplantation. Dr. Kirk earned an M.D. from Duke University School of Medicine, a Ph.D. from Duke University and a B.S. from Old Dominion University.Price Target Changed • Sep 27Price target decreased by 10% to US$16.50Down from US$18.40, the current price target is an average from 6 analysts. New target price is 1,210% above last closing price of US$1.26. Stock is down 54% over the past year. The company is forecast to post a net loss per share of US$2.08 next year compared to a net loss per share of US$6.16 last year.お知らせ • Sep 13Eledon Pharmaceuticals, Inc. Appoints James Robinson to Its Board of Directors, Effective October 1, 2023Eledon Pharmaceuticals, Inc. announced the appointment of James Robinson to its Board of Directors effective October 1, 2023. Mr. Robinson is a seasoned biopharmaceutical executive with over 30 years of experience in the industry, most recently serving as Chief Executive Officer and Director of Urovant Sciences until its merger with Sumitomo Pharma America on July 1, 2023. As Chief Executive Officer and Director of Urovant Sciences, Mr. Robinson guided the company through FDA approval of its first drug, a successful product launch, and its acquisition and take-private transaction by Sumitomo Dainippon Pharma. Prior to Urovant, he was President and Chief Operating Officer of Paragon Biosciences. Before his time at Paragon, Mr. Robinson served as President and COO of Alkermes, leading operations that generated more than $1 billion in annual revenue. Prior to Alkermes, Mr. Robinson spent over 12 years at Astellas Pharma, one of the leaders in the field of solid organ transplant, where he served as President of the Americas and was responsible for approximately $4 billion in revenue generation. Mr. Robinson currently serves on the Board of Directors of UroGen Pharma (Nasdaq: URGN). He previously served on the Board of Directors for Neos Therapeutics and for AGTC before the company was sold to Syncona. Mr. Robinson also previously served on the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA), where he served as Chairman of PhRMA s State Committee. He earned a Bachelor of Science in marketing from DePaul University.お知らせ • Sep 06Eledon Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 2 Bestow Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney TransplantationEledon Pharmaceuticals, Inc. announced the first participant has been dosed in the Company's Phase 2 BESTOW trial evaluating tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant. BESTOW, a multicenter, two-arm, active comparator clinical study, will enroll approximately 120 participants undergoing kidney transplantation in the United States and other countries to evaluate the safety, pharmacokinetics, and efficacy of the anti-CD40 ligand antibody tegoprubart compared to the calcineurin inhibitor tacrolimus. The study's primary objective is to assess graft function at 12 months post-transplant, as measured by estimated glomerular filtration rate (eGFR), in participants treated with tegoprubart compared to tacrolimus. Secondary objectives will include graft survival, biopsy-proven acute rejection, and the incidence of new onset diabetes mellitus after transplant. Eledon will also be using the iBox Scoring System, a composite endpoint of kidney graft function using clinical, histological, and serum biomarkers for the early prediction of graft failure, as an exploratory endpoint. Eledon previously reported results from the first three participants dosed in the Company's ongoing Phase 1b trial. Results showed no incidence of acute rejection and strong graft function observed in all three participants, with mean eGFRs above historical averages with standard of care at measured timepoints out to 31 weeks. The trial currently has enrolled 11 participants to date and will continue in parallel with the Phase 2 BESTOW trial. Eledon expects to report additional data from the ongoing Phase 1b study during the American Society of Nephrology's Kidney Week 2023, taking place November 2-5, 2023 in Philadelphia.お知らせ • Aug 17Eledon Pharmaceuticals, Inc. Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney TransplantationEledon Pharmaceuticals, Inc. announced the dosing of the 10th patient in the company’s ongoing Phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation and will report interim clinical data from this study at the American Society of Nephrology (ASN) Kidney Week Annual Meeting in November 2023. With the dosing of the 10th patient, the Company has now completed the first of two clinical development milestones related to the second tranche closing; the other clinical development milestone related to the second tranche closing is the dosing of the 12th patient in the Phase 2 BESTOW study that is expected to begin enrollment in the 3rd quarter of this year.分析記事 • Aug 10Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • Jul 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$30m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$30m free cash flow). Earnings are forecast to decline by an average of 9.1% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$88m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$30.8m market cap).お知らせ • May 05Eledon Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023Eledon Pharmaceuticals, Inc. announced that they will report Q1, 2023 results After-Market on May 11, 2023分析記事 • Apr 27We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, although...Price Target Changed • Jan 11Price target decreased to US$19.40Down from US$26.80, the current price target is an average from 5 analysts. New target price is 581% above last closing price of US$2.85. Stock is down 37% over the past year. The company is forecast to post a net loss per share of US$2.61 next year compared to a net loss per share of US$2.33 last year.分析記事 • Jan 05Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Sep 06Eledon adds 10% as FDA clears clinical trial for kidney disease candidateThe shares of clinical-stage biotech Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) gained 10% in post-market trading Friday after the company announced that the FDA cleared its Investigational New Drug (IND) application for kidney disease therapy tegoprubart. Phase 2a trial for the candidate is currently underway globally, targeting patients with IgA Nephropathy, which can lead to End-Stage Renal Disease, dialysis, renal transplant, and death with a progressive impact on kidney function. With the IND clearance for tegoprubart in IgA, the company plans to open U.S. trial sites for the open-label study, which will enroll up to 21 patients worldwide in each of the two dose cohorts. Following regulatory clearance in 10 countries to study tegoprubart in IgA, ELDN plans to expand the trial to two more countries, including China. Early August, ELDN announced that the FDA greenlighted a mid-stage trial for tegoprubart as a treatment to prevent organ rejection in patients who underwent a kidney transplant.分析記事 • Aug 31Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Aug 01Eledon gets FDA nod to start trial of organ rejection preventing therapyEledon Pharmaceuticals (NASDAQ:ELDN) said the U.S. Food and Drug Administration (FDA) cleared its investigational new drug application seeking to start a phase 2 trial of tegoprubart for preventing organ rejection in patients receiving a kidney transplant. The study will enroll ~120 people (60 in each group) undergoing kidney transplant who will receive tegoprubart or the active comparator tacrolimus, sold as Prograf by Astellas Pharma (OTCPK:ALPMY) (OTCPK:ALPMF), as part of an immunosuppressive regimen including corticosteroids and mycophenolate mofetil or mycophenolate sodium. The trial's main goal is to assess superiority of graft function by comparing the mean estimated glomerular filtration rate (eGFR) at 12 months post-transplant in one group against the other. Secondary goals include safety, incidence of new onset diabetes, and participant and graft survival. "We believe strongly in tegoprubart’s potential to supplant CNIs in the immunosuppressive regimen of kidney transplant patients, potentially leading to reduced side effects such as diabetes and hypertension, better kidney allograft function, and a resulting longer functional life of transplanted kidneys," said Eledon CEO David-Alexandre Gros.Seeking Alpha • Jul 18Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patientsEledon Pharmaceuticals (NASDAQ:ELDN) said the first patient was dosed in a phase 1b trial of tegoprubart in patients undergoing kidney transplantation. In the study, which received clearance in Canada and the U. K., is enrolling up to 12 patients who will undergo kidney transplantation and will receive tegoprubart in combination with rabbit anti-thymocyte globulin (rATG) induction, and mycophenolate mofetil and an oral steroid taper as maintenance therapy. "We believe tegoprubart has the potential to transform the clinical management of kidney transplantation by preventing graft rejection, mitigating the multiple toxicities associated with CNIs, and ultimately improving long term outcomes," said Eledon CEO David-Alexandre Gros. In June, the U.S. Food and Drug Administration granted orphan drug designation to tegoprubart for preventing allograft rejection in pancreatic islet cell transplantation.Price Target Changed • Apr 27Price target decreased to US$28.80Down from US$32.60, the current price target is an average from 4 analysts. New target price is 857% above last closing price of US$3.01. Stock is down 71% over the past year. The company is forecast to post a net loss per share of US$2.70 next year compared to a net loss per share of US$2.33 last year.Price Target Changed • Nov 15Price target decreased to US$29.75Down from US$32.60, the current price target is an average from 4 analysts. New target price is 435% above last closing price of US$5.56. Stock is down 74% over the past year. The company is forecast to post a net loss per share of US$2.58 next year compared to a net loss per share of US$15.72 last year.Executive Departure • Aug 04Senior VP of Administration & Principal Accounting Officer Jon Kuwahara has left the companyOn the 31st of July, Jon Kuwahara was replaced as CEO by David-Alexander Gros after less than a year in the role. As of March 2021, Jon still personally held only 331.00 shares (US$3.5k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Under Jon's leadership, the company delivered a total shareholder return of 2.1%.Recent Insider Transactions • Jun 15Chief Financial Officer recently bought US$89k worth of stockOn the 11th of June, Paul Little bought around 10k shares on-market at roughly US$8.87 per share. This was the largest purchase by an insider in the last 3 months. This was Paul's only on-market trade for the last 12 months.分析記事 • Apr 14Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth PlansEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is New 90 Day High Low • Mar 10New 90-day low: US$12.66The company is down 36% from its price of US$19.79 on 09 December 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.分析記事 • Feb 21What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?A look at the shareholders of Eledon Pharmaceuticals, Inc. ( NASDAQ:ELDN ) can tell us which group is most powerful...分析記事 • Dec 30Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...Is New 90 Day High Low • Dec 24New 90-day low: US$14.76The company is down 12% from its price of US$16.74 on 24 September 2020. The American market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Price Target Changed • Dec 24Price target raised to US$35.00Up from US$23.70, the current price target is an average from 3 analysts. The new target price is 137% above the current share price of US$14.76. As of last close, the stock is up 34% over the past year.Is New 90 Day High Low • Oct 30New 90-day high: US$21.42The company is up 162% from its price of US$8.19 on 31 July 2020. The American market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.株主還元ELDNUS BiotechsUS 市場7D-1.0%-4.9%-1.0%1Y21.9%28.1%23.3%株主還元を見る業界別リターン: ELDN過去 1 年間で28.1 % の収益を上げたUS Biotechs業界を下回りました。リターン対市場: ELDNは、過去 1 年間で23.3 % のリターンを上げたUS市場を下回りました。価格変動Is ELDN's price volatile compared to industry and market?ELDN volatilityELDN Average Weekly Movement10.2%Biotechs Industry Average Movement10.9%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.2%安定した株価: ELDN 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: ELDNの 週次ボラティリティ ( 10% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/a33DA Groseledon.comエレドン・ファーマシューティカルズは臨床段階のバイオテクノロジー企業である。CD40リガンド（CD40L）経路を標的とする免疫学の専門知識を生かし、移植臓器の保護や拒絶反応の予防、筋萎縮性側索硬化症（ALS）の治療薬を開発している。開発中のリード化合物はテゴプルバートで、CD40リガンドに高い親和性を持つIgG1抗CD40L抗体である。また、腎移植や異種移植における移植片拒絶反応の予防のための製品も開発している。同社はeGenesis, Inc.と共同研究契約を結んでおり、NewcelX Ltd.とは1型糖尿病治療薬NCEL-101の開発に関する戦略的共同研究を行っている。旧社名はNovus Therapeutics, Inc.で、2021年1月に社名をEledon Pharmaceuticals, Inc.に変更した。エレドン・ファーマシューティカルズ・インクはカリフォルニア州アーバインに本社を置いている。もっと見るEledon Pharmaceuticals, Inc. 基礎のまとめEledon Pharmaceuticals の収益と売上を時価総額と比較するとどうか。ELDN 基礎統計学時価総額US$276.74m収益（TTM）-US$78.15m売上高(TTM)n/a0.0xP/Sレシオ-3.8xPER（株価収益率ELDN は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ELDN 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$78.15m収益-US$78.15m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-1.01グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%ELDN の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 22:42終値2026/05/20 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Eledon Pharmaceuticals, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Edward WooAscendiant Capital Markets LLCPete StavropoulosCantor Fitzgerald & Co.Alethia YoungCantor Fitzgerald & Co.6 その他のアナリストを表示
お知らせ • Apr 22Eledon Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2026Eledon Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2026. Location: 19800 macarthur boulevard, suite 250, california., irvine United States
分析記事 • Mar 24Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
お知らせ • Mar 16Eledon Pharmaceuticals Announces Updated Data From Investigator-Initiated Islet Transplant Trial Of Tegoprubart In Patients With Type 1 Diabetes At UChicago MedicineEledon Pharmaceuticals, Inc. announced updated results from an investigator-initiated trial conducted at the University of Chicago Medicine Transplant Institute and presented by Piotr Witkowski, M.D., Ph.D., Director of the Pancreas and Islet Transplant Program at UChicago Medicine, at the Advanced Technologies and Treatments for Diabetes (ATTD) conference, held March 11-14, 2026 in Barcelona, Spain. The investigator-initiated pilot study enrolled 12 adults with long-standing type 1 diabetes undergoing allogeneic islet transplantation at UChicago Medicine. Patients had a median duration of diabetes of approximately 33 years and mean hemoglobin A1C (“HbA1C”) of approximately 8.0% prior to transplantation. Participants received tegoprubart, Eledon’s anti-CD40L monoclonal antibody, as part of a calcineurin inhibitor-free immunosuppression regimen. The data demonstrated rapid improvement in glycemic control following islet transplantation, with stable islet graft function observed across the cohort. All 10 patients who were more than four weeks post-transplant achieved both insulin independence and a most recent HbA1c below 6.0%, with a mean most recent HbA1c across the 10 patients of approximately 5.35%. Tegoprubart-based immunosuppression was generally well tolerated with reported post-transplant immunosuppression-related adverse events successfully treated by lowering the mycophenolic acid dose, if necessary. There were no rejection episodes, and no patients developed de novo donor-specific HLA antibodies. Additionally, no evidence of nephrotoxicity, hypertension or neurotoxicity, which are commonly associated with tacrolimus-based immunosuppression regimens, was observed. These findings further support the potential of CD40L blockade to enable effective islet graft protection while avoiding the toxicities of calcineurin inhibitors. This UChicago Medicine-initiated clinical trial is funded by Breakthrough T1D, with initial support from The Cure Alliance. Breakthrough T1D has also committed to fund a second study evaluating tegoprubart as part of a calcineurin inhibitor-free immunosuppression drug regimen to prevent islet transplant rejection in individuals with T1D and chronic kidney disease. Pancreatic islet transplantation is a minimally invasive procedure developed to provide blood glucose control for subjects with type 1 diabetes and minimize or eliminate dependence on insulin. During the procedure, pancreatic islets containing insulin-producing beta cells are isolated from the pancreas of a deceased organ donor and infused through a small catheter into the patient’s liver. The islet cells lodge in small blood vessels in the liver and release insulin. After the procedure, subjects remain on immunosuppression therapy to prevent transplant rejection.
お知らせ • Mar 10Eledon Pharmaceuticals, Inc. Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver TransplantationEledon Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to tegoprubart for the prevention of allograft rejection in liver transplantation. Tegoprubart has previously received orphan drug designation from the FDA for the prevention of allograft rejection in pancreatic islet cell transplantation and for the treatment of amyotrophic lateral sclerosis (ALS). Orphan Drug Designation is intended to support the development of therapies for rare diseases, defined as conditions affecting fewer than 200,000 people in the United States or fewer than 5 in 10,000 individuals in the European Union. These designations provide sponsors with a range of incentives intended to encourage the development of medicines for diseases with high unmet medical needs.
お知らせ • Jan 23Eledon Pharmaceuticals Presents Long-Term Phase 1B Data for Tegoprubart in Kidney Transplant Patients At the American Society of Transplant Surgeons Winter SymposiumEledon Pharmaceuticals, Inc. announced that it will present 24-month follow-up data from eight patients enrolled in the Phase 1b trial long-term extension evaluating tegoprubart in kidney transplantation at the American Society of Transplant Surgeons Winter Symposium, taking place January 23-25, 2026, in Scottsdale, Arizona. There were no episodes of biopsy-proven acute rejection, graft loss, death, new-onset diabetes mellitus, or de Novo donor-specific antibody formation during the study period. Mean estimated glomerular filtration rate (eGFR) increased over the measurement period, from 67.0 mL/min/1.73 m2 at 12 months to 74.2 mL/min/1. 73 m2 at 24 months.
New Risk • Jan 09New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 33% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (33% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$115m net loss in 3 years).
お知らせ • Apr 22Eledon Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2026Eledon Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2026. Location: 19800 macarthur boulevard, suite 250, california., irvine United States
分析記事 • Mar 24Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
お知らせ • Mar 16Eledon Pharmaceuticals Announces Updated Data From Investigator-Initiated Islet Transplant Trial Of Tegoprubart In Patients With Type 1 Diabetes At UChicago MedicineEledon Pharmaceuticals, Inc. announced updated results from an investigator-initiated trial conducted at the University of Chicago Medicine Transplant Institute and presented by Piotr Witkowski, M.D., Ph.D., Director of the Pancreas and Islet Transplant Program at UChicago Medicine, at the Advanced Technologies and Treatments for Diabetes (ATTD) conference, held March 11-14, 2026 in Barcelona, Spain. The investigator-initiated pilot study enrolled 12 adults with long-standing type 1 diabetes undergoing allogeneic islet transplantation at UChicago Medicine. Patients had a median duration of diabetes of approximately 33 years and mean hemoglobin A1C (“HbA1C”) of approximately 8.0% prior to transplantation. Participants received tegoprubart, Eledon’s anti-CD40L monoclonal antibody, as part of a calcineurin inhibitor-free immunosuppression regimen. The data demonstrated rapid improvement in glycemic control following islet transplantation, with stable islet graft function observed across the cohort. All 10 patients who were more than four weeks post-transplant achieved both insulin independence and a most recent HbA1c below 6.0%, with a mean most recent HbA1c across the 10 patients of approximately 5.35%. Tegoprubart-based immunosuppression was generally well tolerated with reported post-transplant immunosuppression-related adverse events successfully treated by lowering the mycophenolic acid dose, if necessary. There were no rejection episodes, and no patients developed de novo donor-specific HLA antibodies. Additionally, no evidence of nephrotoxicity, hypertension or neurotoxicity, which are commonly associated with tacrolimus-based immunosuppression regimens, was observed. These findings further support the potential of CD40L blockade to enable effective islet graft protection while avoiding the toxicities of calcineurin inhibitors. This UChicago Medicine-initiated clinical trial is funded by Breakthrough T1D, with initial support from The Cure Alliance. Breakthrough T1D has also committed to fund a second study evaluating tegoprubart as part of a calcineurin inhibitor-free immunosuppression drug regimen to prevent islet transplant rejection in individuals with T1D and chronic kidney disease. Pancreatic islet transplantation is a minimally invasive procedure developed to provide blood glucose control for subjects with type 1 diabetes and minimize or eliminate dependence on insulin. During the procedure, pancreatic islets containing insulin-producing beta cells are isolated from the pancreas of a deceased organ donor and infused through a small catheter into the patient’s liver. The islet cells lodge in small blood vessels in the liver and release insulin. After the procedure, subjects remain on immunosuppression therapy to prevent transplant rejection.
お知らせ • Mar 10Eledon Pharmaceuticals, Inc. Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver TransplantationEledon Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to tegoprubart for the prevention of allograft rejection in liver transplantation. Tegoprubart has previously received orphan drug designation from the FDA for the prevention of allograft rejection in pancreatic islet cell transplantation and for the treatment of amyotrophic lateral sclerosis (ALS). Orphan Drug Designation is intended to support the development of therapies for rare diseases, defined as conditions affecting fewer than 200,000 people in the United States or fewer than 5 in 10,000 individuals in the European Union. These designations provide sponsors with a range of incentives intended to encourage the development of medicines for diseases with high unmet medical needs.
お知らせ • Jan 23Eledon Pharmaceuticals Presents Long-Term Phase 1B Data for Tegoprubart in Kidney Transplant Patients At the American Society of Transplant Surgeons Winter SymposiumEledon Pharmaceuticals, Inc. announced that it will present 24-month follow-up data from eight patients enrolled in the Phase 1b trial long-term extension evaluating tegoprubart in kidney transplantation at the American Society of Transplant Surgeons Winter Symposium, taking place January 23-25, 2026, in Scottsdale, Arizona. There were no episodes of biopsy-proven acute rejection, graft loss, death, new-onset diabetes mellitus, or de Novo donor-specific antibody formation during the study period. Mean estimated glomerular filtration rate (eGFR) increased over the measurement period, from 67.0 mL/min/1.73 m2 at 12 months to 74.2 mL/min/1. 73 m2 at 24 months.
New Risk • Jan 09New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 33% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (33% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$115m net loss in 3 years).
お知らせ • Nov 20Eledon Pharmaceuticals, Inc. Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at U Chicago MedicineEledon Pharmaceuticals, Inc. announced preliminary results from an investigator-initiated trial conducted at the University of Chicago Medicine's Transplant Institute and presented at the Rachmiel Levine-Arthur Riggs Diabetes Research Symposium, held November 14-17, 2025 at City of Hope in Los Angeles, California. The ongoing trial, which has been extended to include a total of 12 subjects, is evaluating tegoprubart, Eledon's investigational anti-CD40 Ligand (anti-CD40L) antibody, as the core of a tacrolimus-free immunosuppression drug regimen for the prevention of islet transplant rejection in individuals with type 1 diabetes (T1D). The results, presented by Piotr Witkowski, M.D., Ph.D., Director of the Pancreas and Islet Transplant Program at UChicago Medicine, provide updated preliminary data on the first six subjects in the trial, demonstrating the ability of tegoprubart to prevent the rejection of transplanted islet cells in the absence of calcineurin inhibition resulting in sustained insulin-free management of hemoglobin A1C (HbA1c) in patients with T1D. This clinical trial is funded by Breakthrough T1D (formerly JDRF), with initial support from The Cure Alliance. Breakthrough T1D has also committed to fund a second study evaluating tegoprubart as part of a calcineurin inhibitor-free immunosuppression Drug regimen to prevent islet transplant rejection in individuals With T1D and chronic kidney disease. Post-procedure, subjects remain on immunosuppression therapy to prevent transplant rejection.
New Risk • Nov 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings are forecast to decline by an average of 15% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$129m net loss in 3 years). Shareholders have been diluted in the past year (26% increase in shares outstanding).
New Risk • Nov 16New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$83m Forecast net loss in 3 years: US$129m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings are forecast to decline by an average of 15% per year for the foreseeable future. Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$129m net loss in 3 years).
お知らせ • Nov 13Eledon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $49.986448 million.Eledon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $49.986448 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 15,152,485 Price\Range: $1.65 Discount Per Security: $0.099 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 15,151,515 Price\Range: $1.649 Discount Per Security: $0.099
Price Target Changed • Nov 12Price target decreased by 14% to US$8.17Down from US$9.50, the current price target is an average from 6 analysts. New target price is 332% above last closing price of US$1.89. Stock is down 56% over the past year. The company is forecast to post a net loss per share of US$0.83 next year compared to a net loss per share of US$0.75 last year.
お知らせ • Nov 12Eledon Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.Eledon Pharmaceuticals, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Security Name: Pre-Funded Warrants Security Type: Equity Warrant
Price Target Changed • Nov 10Price target decreased by 12% to US$9.00Down from US$10.20, the current price target is an average from 6 analysts. New target price is 337% above last closing price of US$2.06. Stock is down 58% over the past year. The company is forecast to post a net loss per share of US$0.82 next year compared to a net loss per share of US$0.75 last year.
お知らせ • Nov 07Eledon Pharmaceuticals, Inc. Presents Phase 2 Bestow Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation At the American Society of Nephrology's Kidney Week 2025 Annual MeetingEledon Pharmaceuticals, Inc. announced results from its Phase 2 BESTOW trial evaluating tegoprubart for the prevention of organ rejection in patients receiving a de novo kidney transplant. Results from the Phase 2 BESTOW clinical trial were presented as a late breaking oral presentation titled "Efficacy and Safety of Tegoprubart for the Prevention of Rejection in Kidney Transplantation: Results from the Phase 2 BESTow Trial," at the American Society of Nephrology's Kidney Week 2025 Annual Meeting in Houston, TX. The study's primary efficacy endpoint was the change in eGFR at 12 months post-transplant. Secondary endpoints included biopsy-proven acute rejection (BPAR), patient and graft survival, composite efficacy failure, iBox score, donor-specific antibodies (DSAs), delayed graft function (DGF), and new-onset diabetes after transplantation (NODAT). Safety findings underscore tegoprubart's potential to maintain effective immunosuppression while minimizing the metabolic, neurologic, and cardiovascular toxicities characteristic of tacrolimus-based therapy. eGFR on tegoprubart treatment was 69 mL/min/1.73 m2 (n=51) at 12 months vs. 66 mL/min/1. 73 m2 for tacrolimus (n=56). Although the primary endpoint did not reach statistical significance, tegoprubart maintained strong renal function, delivering what the Company believes is the highest mean eGFR level reported to date in kidney transplant clinical trials evaluating rejection prevention. Subgroup analyses demonstrated higher eGFRs in nearly all tegoprubart subgroups compared with tacrolimus, particularly among living-related donor recipients (72 mL/min/1.74 m2 vs. 62 mL/min/1.72 m2) and high Kidney Donor Profile Index (KDPI > 35) transplants (62 mL/min/1.83 m2 vs. 53 mL/min/1.1.73 m2). The efficacy failure composite endpoint, comprising death, graft loss and biopsy proven acute rejection, is the approval endpoint currently recognized by the U.S. Food and Drug Administration.
Valuation Update With 7 Day Price Move • Nov 02Investor sentiment improves as stock rises 24%After last week's 24% share price gain to US$4.32, the stock trades at a trailing P/E ratio of 17.7x. Average trailing P/E is 18x in the Biotechs industry in the US. Total returns to shareholders of 79% over the past three years.
Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improves as stock rises 26%After last week's 26% share price gain to US$3.44, the stock trades at a trailing P/E ratio of 14.1x. Average trailing P/E is 16x in the Biotechs industry in the US. Total returns to shareholders of 45% over the past three years.
お知らせ • Oct 17Eledon Pharmaceuticals to Present Results from Phase 2 Bestow Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual MeetingEledon Pharmaceuticals, Inc. announced an oral presentation will be featured at the American Society of Nephrology's upcoming Kidney Week 2025 Annual Meeting taking place in Houston, TX, from November 5-8, 2025. The oral presentation will highlightline results from the Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation.
New Risk • Aug 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 21% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (52% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$124m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change).
お知らせ • Aug 07Eledon Pharmaceuticals, Inc. Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney TransplantationEledon Pharmaceuticals, Inc. announced updated data from the Company's ongoing open-label Phase 1b trial evaluating tegoprubart for the prevention of organ rejection in kidney transplant patients. Results from the oral presentation, titled "Tegoprubart, an Anti-CD40L Antibody, for the Prevention of Rejection in Kidney Transplantation: An Ongoing Phase 1b Study," were presented at the World Transplant Congress (WTC) taking place in San Francisco, CA. Data from historical studies using the standard of care, calcineurin inhibitor-based immunosuppression therapy, typically report aggregate mean estimated glomerular filtration rates (eGFRs) of approximately 53 mL/min/1.73 m2 during the first year after kidney transplant. In addition, preliminary abbreviated iBox data was presented suggesting that tegoprubart may improve 5-year graft survival. Abbreviated iBox, a composite biomarker panel developed by the Paris Transplant Group, incorporates kidney function (eGFR, proteinuria) and immunologic response (donor-specific antibodies) parameters into a single prognostic score. Of the patients who experienced a rejection episode and completed a year in the study, three who remained on tegoprubart had a mean eGFR of approximately 73 mL/min/1. 73 m2 at 12 months, indicating full recovery of kidney function, while the two patients who switched to standard of care tacrolimus had a mean eGFR the mean eGFR of approximately 34 mL/min/1.73 m2 at 12 months.
お知らせ • Jul 09Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance A Potential Functional Cure for Type 1 DiabetesSernova Biotherapeutics announced a Collaborative Research Agreement with Eledon Pharmaceuticals, Inc. to evaluate Eledon's immunosuppressive agent tegoprubart (AT-1501) in Sernova's ongoing Phase 1/2 clinical trial of its Cell Pouch Bio-hybrid Organ in patients with type 1 diabetes (T1D). Under the terms of the agreement, Eledon will supply tegoprubart, an investigational anti-CD40L antibody being evaluated for its potential to prevent transplant rejection in islet cell, kidney and xeno transplantation, will be used in place of tacrolimus in the upcoming Cohort C of Sernova's Phase 1/2 clinical trial. Tacrolimus is currently a standard immunosuppressive drug used in organ transplantation to prevent rejection. However, its potential toxicity, particularly toward insulin-producing beta cells, and its side effect profile limit its suitability as an optimal immunosuppressive agent for islet cell therapy in T1D. In an investigator-initiated study led by Dr. Piotr Witkowski, a leading expert in islet transplantation at the University of Chicago, T1D patients received islet transplants along with tegoprubart to prevent rejection. Islet engraftment, measured by graft function standardized to the number of islets infused, was three to five times higher than in comparable subjects outside this study who received tacrolimus-based immunosuppression, suggesting treatment with tegoprubart better protects transplanted islets resulting in improved graft survival and function. Treatment was generally well tolerated in all subjects with no unexpected adverse events or severe hypoglycemic episodes. This collaboration highlights the shared commitment of both companies to address the unmet needs of individuals living with T1D. By combining their expertise and leveraging complementary technologies, Sernova and Eledon aim to deliver a therapeutic solution that offers a durable and effective alternative to daily insulin injections and current immunosuppressive protocols.
Price Target Changed • May 21Price target decreased by 12% to US$9.00Down from US$10.20, the current price target is an average from 4 analysts. New target price is 186% above last closing price of US$3.15. Stock is up 5.4% over the past year. The company is forecast to post a net loss per share of US$0.87 next year compared to a net loss per share of US$0.75 last year.
分析記事 • May 07Companies Like Eledon Pharmaceuticals (NASDAQ:ELDN) Are In A Position To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
お知らせ • Apr 15Eledon Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2025Eledon Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2025. Location: at 19800 macarthur boulevard, suite 250, california, irvine United States
Seeking Alpha • Jan 28Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management BusinessSummary Eledon Pharmaceuticals' Tegoprubart, a second-gen anti-CD40L antibody, shows promise in preventing organ rejection without thromboembolic risks, addressing unmet needs in kidney and islet cell transplantation. Early trials indicate Tegoprubart's safety and efficacy, with no major side effects and better kidney function compared to current standards like tacrolimus. Eledon has a market cap of $264mn, a cash balance of $78mn, and a cash runway of 7-8 quarters, but remains a high-risk investment. While it's too early for large investments, a small pilot position could be warranted based on promising early data and unmet medical needs. Read the full article on Seeking Alpha
Price Target Changed • Nov 14Price target decreased by 20% to US$12.50Down from US$15.60, the current price target is an average from 5 analysts. New target price is 193% above last closing price of US$4.27. Stock is up 242% over the past year. The company is forecast to post a net loss per share of US$1.16 next year compared to a net loss per share of US$4.73 last year.
お知らせ • Oct 30+ 2 more updatesEledon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $84.9951 million.Eledon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $84.9951 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 18,356,173 Price\Range: $3.65 Discount Per Security: $0.219 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 4,931,507 Price\Range: $3.649 Discount Per Security: $0.219
Seeking Alpha • Oct 29Eledon: Changing Scope Of Immunosuppressive Drug Space With TegoprubartSummary Positive phase 1b biomarker and eGFR data achieved from phase 1b study using tegoprubart for prevention of organ rejection in kidney transplant patients. Top-line data from the phase 2 BESTOW study, using tegoprubart for prevention of organ rejection in kidney transplant patients, expected in Q4 of 2025. The organ transplant immunosuppressant drugs market is expected to reach $6.4 billion by 2030. Positive data obtained from investigator-sponsored phase 1/2 trial, using tegoprubart for islet cell transplantation in patients with Type 1 Diabetes. Read the full article on Seeking Alpha
お知らせ • Sep 21Eledon Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.Eledon Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
お知らせ • Aug 15Eledon Pharmaceuticals, Inc. announced delayed 10-Q filingOn 08/14/2024, Eledon Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jul 29Eledon Pharmaceuticals, Inc. Provides Enrollment Update for Phase 2 Bestow Trial Assessing Tegoprubart for the Prevention of Organ RejectionEledon Pharmaceuticals, Inc. announced that it has enrolled the 80th participant in its ongoing Phase 2 BESTOW trial assessing tegoprubart for the prevention of rejection in kidney transplantation. This progress underscores the urgency and need for innovative solutions in preventing kidney transplant rejection. The study's primary objective is to assess graft function at 12 months post-transplant, as measured by estimated glomerular filtration rate (eGFR), in participants treated with tegoprubart compared to tacrolimus. Better graft function as assessed by eGFR has been associated with improved long-term patient and graft survival. Eledon is currently conducting a Phase 2 trial (BESTOW; NCT05983770), a Phase 1b trial (NCT05027906), and a long-term safety and efficacy extension study (NCT06126380) to evaluate tegop Rubart for the prevention of organ rejection in patients receiving a kidney transplant.
お知らせ • Jun 05Eledon Pharmaceuticals, Inc. Presents Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney TransplantationEledon Pharmaceuticals, Inc. presented updated data from the Company’s ongoing open-label Phase 1b trial and open-label extension study evaluating tegoprubart for the prevention of organ rejection in kidney transplant patients. Results from the poster, titled “Biomarkers of Inflammation and eGFR in an Ongoing Phase 1B Study of an Anti-CD40L Antibody Tegoprubart, for the Prevention of Rejection in Kidney Transplant,” were presented at the American Transplant Congress (ATC) taking place in Philadelphia, PA from June 1-5, 2024. As of the April 2024 cutoff date, updated data from the 13 participants in the ongoing Phase 1b trial support tegoprubart’s potential to protect organ function in patients undergoing kidney transplantation. Data from historical studies using standard of care, calcineurin inhibitor-based immunosuppression therapy typically report aggregate mean estimated glomerular filtration rates (eGFRs) of approximately 50 mL/min/1.73m2 during the first year after kidney transplant. In the ongoing Phase 1b trial, mean eGFR was above 60 mL/min/1.73m² at each reported time points after day 30, with an overall mean eGFR of 70.5 mL/min/1.73m² for all the reported time points after day 30 post-transplant. Two participants completed 12 months on therapy post-transplant, and both demonstrated mean eGFRs above 90 mL/min/1.73m² at one-year post-transplant. Results demonstrated that tegoprubart is generally safe and well tolerated in patients undergoing de novo kidney transplantation. Three subjects have discontinued the study due to hair loss and fatigue, viral infection, and rejection, respectively. There have been no cases of hyperglycemia, new onset diabetes, or tremor, all of which are side effects often associated with standard of care immunosuppression therapy. There have been no cases of graft loss or death. Eledon is currently conducting a Phase 1b trial (NCT05027906), a Phase 2 trial (BESTOW; NCT05983770), and a long-term safety and efficacy extension study (NCT06126380) to evaluate tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant.
お知らせ • Jun 02Eledon Pharmaceuticals, Inc., Annual General Meeting, Jul 10, 2024Eledon Pharmaceuticals, Inc., Annual General Meeting, Jul 10, 2024. Location: 19800 macarthur boulevard, suite 250, california, irvine United States
New Risk • May 27New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 71% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 18% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (71% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$75m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change).
Price Target Changed • May 10Price target decreased by 10% to US$14.00Down from US$15.60, the current price target is an average from 5 analysts. New target price is 506% above last closing price of US$2.31. Stock is down 4.1% over the past year. The company is forecast to post a net loss per share of US$1.24 next year compared to a net loss per share of US$1.64 last year.
お知らせ • May 08+ 1 more updateEledon Pharmaceuticals, Inc. announced that it expects to receive $49.99901 million in fundingEledon Pharmaceuticals, Inc. announced that it has entered into a Securities Purchase Agreement with certain institutional and accredited investors to issue 13,110,484 shares of the common stock, $0.001 par value per share at a price of $2.37 per share for the gross proceeds of $31,071,847.08 and 7,989,516 pre-funded warrants at a price of $2.369 per warrant for the gross proceeds of $18,927,163.404; for total gross proceeds of $49,999,010.484 on May 6, 2024. The warrants are exercisable to purchase 7,989,516 shares of Common Stock at an exercise price of $0.001 per share. The Pre-Funded Warrants were issued in lieu of shares of Common Stock and are exercisable immediately and until exercised in full. The closing of the Private Placement is expected to occur the week of May 6, 2024. The Shares, the Pre-Funded Warrants, and the shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants, have not been registered under the Securities Act of 1933, as amended, and were offered pursuant to the exemption from registration provided in Section 4(a)(2) under the Securities Act of 1933, as amended, and Rule 506(b) promulgated thereunder.
New Risk • Apr 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 25% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (80% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$90m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$49.4m market cap).
お知らせ • Mar 26Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ RejectionEledon Pharmaceuticals, Inc. announced the enrollment of the 12th participant on March 23, 2024, in the Company’s ongoing Phase 2 BESTOW trial assessing tegoprubart head-to-head with tacrolimus for the prevention of rejection in kidney transplantation.
分析記事 • Mar 22We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth CarefullyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Dec 05Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
お知らせ • Nov 03Eledon Pharmaceuticals, Inc. Reports Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney TransplantationEledon Pharmaceuticals, Inc. reported results from the Company's ongoing Phase 1b open-label trial evaluating tegoprubart for the prevention of rejection in patients undergoing de novo kidney transplantation. Results were presented at the American Society of Nephrology Kidney Week 2023 Annual Meeting taking place in Philadelphia, PA from November 2-5, 2023. Aggregate mean estimated glomerular filtration rate (eGFR) -- a measure of kidney function -- was above 70 mL/min/1.73m(2) at all reported time points after day 90. Historical studies have reported average eGFRs generally in the low 50 mL/min/1. 73m(2) range during the first year after kidney transplant using standard of care. One participant has completed the study with an eGFR of 91 at one year (day 374) and is now enrolled in a Phase 2 open-label extension (OLE) study, which will evaluate the long-term safety, pharmacokinetics, and efficacy of tegoprubart in participants who have completed one year of treatment in either the ongoing Phase 1b or Phase 2 BESTOW study. The Phase 1b open-label study has enrolled 11 participants who underwent kidney transplantation in Canada, Australia, and the United Kingdom. The webcast will be archived on the website following the completion of the call.
お知らせ • Oct 24Eledon Pharmaceuticals, Inc. Appoints of Eliezer Katz as Chief Medical OfficerEledon Pharmaceuticals, Inc. announced the appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer with responsibility for leading the company’s clinical development programs. Dr. Katz is an experienced transplant surgeon with significant clinical development experience. Most recently, he was Chief Medical Officer at eGenesis where he helped lead the clinical development of eGenesis’ xenotransplantation programs. Prior to eGenesis, Dr. Katz was Vice President of Clinical Development first at Viela Bio and then at Horizon Therapeutics following its acquisition of Vielo Bio. At Horizon and Viela Bio, Dr. Katz led the clinical development of inebilizumab in multiple autoimmune indications and oversaw the regulatory submission and approval of UPLIZNA(inebilizumab) to treat neuromyelitis optica spectrum disorder in adults. Prior to Viela Bio, Dr. Katz served as Senior Director of Clinical Development at MedImmune Inc. where he oversaw the clinical development of three different biologics. Prior to MedImmune, Dr. Katz served as Senior Director of Transplantation with the Medicine Development Group at Pfizer. At Pfizer, he oversaw multiple research programs with rapamycin, an anti-rejection drug, and was instrumental in the regulatory submission and FDA approval of rapamycin as a treatment for lymphangioleiomyomatosis (LAM), a rare and fatal lung disease. Before joining industry, Dr. Katz spent two decades as a transplant surgeon. He was director of the abdominal transplantation division at Integris Baptist Medical Center in Oklahoma City, and an associate professor of surgery and the director of the liver transplantation division at the University of Massachusetts Medical Center, Worcester, MA.Dr. Katz spearheaded liver transplantation advances at these institutions and was actively involved with policy making in organ donation and allocation. Dr. Katz earned his M.D. at Hadassah Hebrew University Medical School in Jerusalem.
Board Change • Oct 13Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. Director Jim Robinson was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 05Eledon Pharmaceuticals Appoints Allan Douglas Kirk to Board of DirectorsEledon Pharmaceuticals, Inc. announced the appointment of Allan Douglas Kirk, M.D., Ph.D., to its Board of Directors. Dr. Kirk is internationally recognized for his work in organ transplantation, with a specialized focus on kidney transplants and transplant immunology. He is currently Chairman of the Department of Surgery and Surgeon-in-Chief at Duke University School of Medicine. He is also the David C. Sabiston, Jr. Professor of Surgery, a Professor of Integrative Immunobiology, and a Professor of Pediatrics at Duke. Dr. Kirk served as the inaugural Chief of the Transplantation Branch for the National Institute of Diabetes and Digestive and Kidney Diseases and has been a principal investigator for multiple clinical trials, including the first-in-human experience with novel immunosuppressive agents. Dr. Kirk has helped pioneer the use of co-stimulation pathway blockade to prevent organ rejection in transplant patients. He has a special interest in immune management of transplant recipients, including therapies that influence T cell co-stimulation pathways and adjuvant therapies that facilitate co-stimulation blockade to prevent the rejection of transplanted organs without undue suppression of protective immunity. His research is directed toward understanding transplant rejection and translating this understanding into improved therapies for transplant recipients. He has co-authored hundreds of peer-reviewed journal publications. Dr. Kirk is a member of the Duke Transplant Center and is a core faculty member of the Duke Innovation & Entrepreneurship program. He also previously served as Editor-in-Chief for the American Journal of Transplantation. Dr. Kirk earned an M.D. from Duke University School of Medicine, a Ph.D. from Duke University and a B.S. from Old Dominion University.
Price Target Changed • Sep 27Price target decreased by 10% to US$16.50Down from US$18.40, the current price target is an average from 6 analysts. New target price is 1,210% above last closing price of US$1.26. Stock is down 54% over the past year. The company is forecast to post a net loss per share of US$2.08 next year compared to a net loss per share of US$6.16 last year.
お知らせ • Sep 13Eledon Pharmaceuticals, Inc. Appoints James Robinson to Its Board of Directors, Effective October 1, 2023Eledon Pharmaceuticals, Inc. announced the appointment of James Robinson to its Board of Directors effective October 1, 2023. Mr. Robinson is a seasoned biopharmaceutical executive with over 30 years of experience in the industry, most recently serving as Chief Executive Officer and Director of Urovant Sciences until its merger with Sumitomo Pharma America on July 1, 2023. As Chief Executive Officer and Director of Urovant Sciences, Mr. Robinson guided the company through FDA approval of its first drug, a successful product launch, and its acquisition and take-private transaction by Sumitomo Dainippon Pharma. Prior to Urovant, he was President and Chief Operating Officer of Paragon Biosciences. Before his time at Paragon, Mr. Robinson served as President and COO of Alkermes, leading operations that generated more than $1 billion in annual revenue. Prior to Alkermes, Mr. Robinson spent over 12 years at Astellas Pharma, one of the leaders in the field of solid organ transplant, where he served as President of the Americas and was responsible for approximately $4 billion in revenue generation. Mr. Robinson currently serves on the Board of Directors of UroGen Pharma (Nasdaq: URGN). He previously served on the Board of Directors for Neos Therapeutics and for AGTC before the company was sold to Syncona. Mr. Robinson also previously served on the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA), where he served as Chairman of PhRMA s State Committee. He earned a Bachelor of Science in marketing from DePaul University.
お知らせ • Sep 06Eledon Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 2 Bestow Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney TransplantationEledon Pharmaceuticals, Inc. announced the first participant has been dosed in the Company's Phase 2 BESTOW trial evaluating tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant. BESTOW, a multicenter, two-arm, active comparator clinical study, will enroll approximately 120 participants undergoing kidney transplantation in the United States and other countries to evaluate the safety, pharmacokinetics, and efficacy of the anti-CD40 ligand antibody tegoprubart compared to the calcineurin inhibitor tacrolimus. The study's primary objective is to assess graft function at 12 months post-transplant, as measured by estimated glomerular filtration rate (eGFR), in participants treated with tegoprubart compared to tacrolimus. Secondary objectives will include graft survival, biopsy-proven acute rejection, and the incidence of new onset diabetes mellitus after transplant. Eledon will also be using the iBox Scoring System, a composite endpoint of kidney graft function using clinical, histological, and serum biomarkers for the early prediction of graft failure, as an exploratory endpoint. Eledon previously reported results from the first three participants dosed in the Company's ongoing Phase 1b trial. Results showed no incidence of acute rejection and strong graft function observed in all three participants, with mean eGFRs above historical averages with standard of care at measured timepoints out to 31 weeks. The trial currently has enrolled 11 participants to date and will continue in parallel with the Phase 2 BESTOW trial. Eledon expects to report additional data from the ongoing Phase 1b study during the American Society of Nephrology's Kidney Week 2023, taking place November 2-5, 2023 in Philadelphia.
お知らせ • Aug 17Eledon Pharmaceuticals, Inc. Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney TransplantationEledon Pharmaceuticals, Inc. announced the dosing of the 10th patient in the company’s ongoing Phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation and will report interim clinical data from this study at the American Society of Nephrology (ASN) Kidney Week Annual Meeting in November 2023. With the dosing of the 10th patient, the Company has now completed the first of two clinical development milestones related to the second tranche closing; the other clinical development milestone related to the second tranche closing is the dosing of the 12th patient in the Phase 2 BESTOW study that is expected to begin enrollment in the 3rd quarter of this year.
分析記事 • Aug 10Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • Jul 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$30m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$30m free cash flow). Earnings are forecast to decline by an average of 9.1% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$88m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$30.8m market cap).
お知らせ • May 05Eledon Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023Eledon Pharmaceuticals, Inc. announced that they will report Q1, 2023 results After-Market on May 11, 2023
分析記事 • Apr 27We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Price Target Changed • Jan 11Price target decreased to US$19.40Down from US$26.80, the current price target is an average from 5 analysts. New target price is 581% above last closing price of US$2.85. Stock is down 37% over the past year. The company is forecast to post a net loss per share of US$2.61 next year compared to a net loss per share of US$2.33 last year.
分析記事 • Jan 05Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 06Eledon adds 10% as FDA clears clinical trial for kidney disease candidateThe shares of clinical-stage biotech Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) gained 10% in post-market trading Friday after the company announced that the FDA cleared its Investigational New Drug (IND) application for kidney disease therapy tegoprubart. Phase 2a trial for the candidate is currently underway globally, targeting patients with IgA Nephropathy, which can lead to End-Stage Renal Disease, dialysis, renal transplant, and death with a progressive impact on kidney function. With the IND clearance for tegoprubart in IgA, the company plans to open U.S. trial sites for the open-label study, which will enroll up to 21 patients worldwide in each of the two dose cohorts. Following regulatory clearance in 10 countries to study tegoprubart in IgA, ELDN plans to expand the trial to two more countries, including China. Early August, ELDN announced that the FDA greenlighted a mid-stage trial for tegoprubart as a treatment to prevent organ rejection in patients who underwent a kidney transplant.
分析記事 • Aug 31Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Aug 01Eledon gets FDA nod to start trial of organ rejection preventing therapyEledon Pharmaceuticals (NASDAQ:ELDN) said the U.S. Food and Drug Administration (FDA) cleared its investigational new drug application seeking to start a phase 2 trial of tegoprubart for preventing organ rejection in patients receiving a kidney transplant. The study will enroll ~120 people (60 in each group) undergoing kidney transplant who will receive tegoprubart or the active comparator tacrolimus, sold as Prograf by Astellas Pharma (OTCPK:ALPMY) (OTCPK:ALPMF), as part of an immunosuppressive regimen including corticosteroids and mycophenolate mofetil or mycophenolate sodium. The trial's main goal is to assess superiority of graft function by comparing the mean estimated glomerular filtration rate (eGFR) at 12 months post-transplant in one group against the other. Secondary goals include safety, incidence of new onset diabetes, and participant and graft survival. "We believe strongly in tegoprubart’s potential to supplant CNIs in the immunosuppressive regimen of kidney transplant patients, potentially leading to reduced side effects such as diabetes and hypertension, better kidney allograft function, and a resulting longer functional life of transplanted kidneys," said Eledon CEO David-Alexandre Gros.
Seeking Alpha • Jul 18Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patientsEledon Pharmaceuticals (NASDAQ:ELDN) said the first patient was dosed in a phase 1b trial of tegoprubart in patients undergoing kidney transplantation. In the study, which received clearance in Canada and the U. K., is enrolling up to 12 patients who will undergo kidney transplantation and will receive tegoprubart in combination with rabbit anti-thymocyte globulin (rATG) induction, and mycophenolate mofetil and an oral steroid taper as maintenance therapy. "We believe tegoprubart has the potential to transform the clinical management of kidney transplantation by preventing graft rejection, mitigating the multiple toxicities associated with CNIs, and ultimately improving long term outcomes," said Eledon CEO David-Alexandre Gros. In June, the U.S. Food and Drug Administration granted orphan drug designation to tegoprubart for preventing allograft rejection in pancreatic islet cell transplantation.
Price Target Changed • Apr 27Price target decreased to US$28.80Down from US$32.60, the current price target is an average from 4 analysts. New target price is 857% above last closing price of US$3.01. Stock is down 71% over the past year. The company is forecast to post a net loss per share of US$2.70 next year compared to a net loss per share of US$2.33 last year.
Price Target Changed • Nov 15Price target decreased to US$29.75Down from US$32.60, the current price target is an average from 4 analysts. New target price is 435% above last closing price of US$5.56. Stock is down 74% over the past year. The company is forecast to post a net loss per share of US$2.58 next year compared to a net loss per share of US$15.72 last year.
Executive Departure • Aug 04Senior VP of Administration & Principal Accounting Officer Jon Kuwahara has left the companyOn the 31st of July, Jon Kuwahara was replaced as CEO by David-Alexander Gros after less than a year in the role. As of March 2021, Jon still personally held only 331.00 shares (US$3.5k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Under Jon's leadership, the company delivered a total shareholder return of 2.1%.
Recent Insider Transactions • Jun 15Chief Financial Officer recently bought US$89k worth of stockOn the 11th of June, Paul Little bought around 10k shares on-market at roughly US$8.87 per share. This was the largest purchase by an insider in the last 3 months. This was Paul's only on-market trade for the last 12 months.
分析記事 • Apr 14Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth PlansEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Is New 90 Day High Low • Mar 10New 90-day low: US$12.66The company is down 36% from its price of US$19.79 on 09 December 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.
分析記事 • Feb 21What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?A look at the shareholders of Eledon Pharmaceuticals, Inc. ( NASDAQ:ELDN ) can tell us which group is most powerful...
分析記事 • Dec 30Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Is New 90 Day High Low • Dec 24New 90-day low: US$14.76The company is down 12% from its price of US$16.74 on 24 September 2020. The American market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Price Target Changed • Dec 24Price target raised to US$35.00Up from US$23.70, the current price target is an average from 3 analysts. The new target price is 137% above the current share price of US$14.76. As of last close, the stock is up 34% over the past year.
Is New 90 Day High Low • Oct 30New 90-day high: US$21.42The company is up 162% from its price of US$8.19 on 31 July 2020. The American market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
